By Suherman Candra Maholtra 
A team of scientists led by investigators from NYU Langone Health and the Perlmutter Cancer Center has identified a critical molecular driver that simultaneously fuels the growth of melanoma and enables tumors to bypass the body’s natural immune defenses. The study, published in the high-impact journal Cancer Discovery, highlights the transcription factor HOXD13 as a master regulator of the biological processes that allow skin cancer to flourish. By controlling the formation of new blood vessels and creating a chemical barrier against immune cells, HOXD13 has emerged as a high-priority target for future combination therapies aimed at treating aggressive forms of the disease.
The discovery addresses one of the most significant challenges in modern oncology: understanding why some tumors remain "cold," or resistant to the immune system’s efforts to destroy them. While immunotherapy has revolutionized melanoma treatment over the last decade, a substantial portion of patients either do not respond to these treatments or eventually develop resistance. The NYU Langone research suggests that HOXD13 activity may be a primary reason for this resistance, offering a new roadmap for personalized medicine in skin cancer care.
The Dual Role of HOXD13 in Cancer Progression
Transcription factors are specialized proteins that act as master switches within the cell. They bind to specific sequences of DNA to turn genes on or off, thereby controlling the production of proteins that dictate cell behavior. In the context of embryonic development, HOXD13 is known for its role in limb and digit formation. However, the new research demonstrates that melanoma cells "hijack" this developmental protein to facilitate their own survival and expansion.
The researchers found that HOXD13 exerts its influence through two distinct but complementary mechanisms. First, it promotes angiogenesis—the physiological process through which new blood vessels form from pre-existing vessels. Tumors require a robust blood supply to obtain the oxygen and nutrients necessary for rapid growth. Without this supply, cancerous masses would remain small and localized. HOXD13 ensures this supply by activating several key pathways, most notably those involving vascular endothelial growth factor (VEGF), a well-known stimulant of blood vessel growth.
Second, HOXD13 orchestrates a complex "immune evasion" strategy. The study revealed that high levels of this transcription factor correlate with a significant reduction in the infiltration of cytotoxic T cells—the "soldiers" of the immune system tasked with killing cancer cells. By altering the tumor microenvironment, HOXD13 effectively builds a wall around the tumor, preventing immune cells from entering and attacking the malignancy.
Deciphering the Chemical Shield: Adenosine and CD73
A critical component of the NYU Langone study was the identification of how HOXD13 creates this immune-resistant environment. The research team discovered that HOXD13 increases the expression of CD73, an enzyme found on the surface of cells. CD73 plays a pivotal role in the production of adenosine, a signaling molecule that typically helps regulate inflammation in healthy tissue.
In the context of a tumor, however, high levels of adenosine act as a potent immunosuppressant. Adenosine binds to receptors on T cells, effectively "switching them off" or slowing their movement. This chemical barrier prevents T cells from penetrating the tumor core, leaving the cancer free to proliferate. When the researchers experimentally reduced HOXD13 activity in laboratory models, they observed a dramatic reversal: CD73 levels dropped, adenosine concentrations decreased, and T cells were once again able to infiltrate and attack the tumors.
This specific pathway—HOXD13 to CD73 to adenosine—explains why many melanomas are able to resist current PD-1 or CTLA-4 inhibitors, which are the standard-of-care immunotherapies. If the T cells are chemically blocked from entering the tumor in the first place, these drugs have no target to activate.
Methodology and Global Collaborative Efforts
The findings are the result of a multi-year, international collaboration that spanned continents and utilized diverse datasets. To ensure the findings were broadly applicable, the research team analyzed tumor samples from more than 200 melanoma patients across the United States, Brazil, and Mexico. This international scope was crucial, as it allowed scientists to observe how HOXD13 behaves across different genetic backgrounds and clinical settings.
The researchers utilized advanced genomic sequencing and bioinformatics to identify which transcription factors were most active in aggressive tumors. HOXD13 consistently appeared as a top candidate. Following the human data analysis, the team moved to "in vivo" and "in vitro" experiments. Using mouse models and human melanoma cell lines, they confirmed that artificially boosting HOXD13 accelerated tumor growth, while inhibiting it led to tumor shrinkage and improved immune response.
"Our study provides new evidence that transcription factor HOXD13 is a potent driver of melanoma growth and that it suppresses the T cell activity needed to fight the disease," stated Dr. Pietro Berico, the study’s lead investigator and a postdoctoral research fellow at the NYU Grossman School of Medicine. Dr. Berico emphasized that understanding the "cross-talk" between blood vessel growth and immune suppression is vital for the next generation of cancer treatments.
Clinical Implications and Potential Combination Therapies
The identification of HOXD13 as a central regulator opens the door for a "double-barreled" therapeutic approach. Currently, there are existing drugs that target VEGF (to stop blood vessel growth) and others in clinical development that target adenosine receptors (to remove the immune barrier).
Dr. Eva Hernando-Monge, the study’s senior investigator and a professor in the Department of Pathology at NYU Grossman School of Medicine, noted that the data supports a combined targeting strategy. "This data supports the combined targeting of angiogenesis and adenosine-receptor pathways as a promising new treatment approach for HOXD13-driven melanoma," she explained.
Several clinical trials are already underway investigating the efficacy of blocking VEGF and adenosine in various cancers. The NYU team’s research provides a biological rationale for focusing these trials specifically on patients with high HOXD13 expression. By using HOXD13 as a biomarker, doctors could potentially identify which patients are most likely to benefit from these specific drug combinations, moving closer to the goal of precision oncology.
Beyond Melanoma: Applications in Other Cancers
While the primary focus of the study was melanoma, the researchers believe the HOXD13 pathway may be relevant to several other deadly forms of cancer. Initial genomic surveys conducted by the team suggest that HOXD13 is also elevated in certain glioblastomas (aggressive brain tumors), sarcomas (cancers of the connective tissues), and osteosarcomas (bone cancer).
These types of cancers are notoriously difficult to treat and often share the same characteristics as aggressive melanoma: they are highly vascularized and highly resistant to the immune system. The research team intends to investigate whether the HOXD13-CD73-adenosine axis operates similarly in these malignancies. If proven, the therapeutic strategies developed for melanoma could be adapted to treat a much wider range of patients.
Chronology of Research and Future Milestones
The study represents a significant milestone in a timeline of research dedicated to transcription factors in cancer. Over the last decade, the scientific community has moved from simply identifying genetic mutations to understanding the regulatory networks—like the one controlled by HOXD13—that govern how those mutations are expressed.
- 2018–2020: Initial genomic screening of melanoma patient cohorts identifies HOXD13 as a potential factor in tumor progression.
- 2021: International partnerships are solidified with institutions in Mexico and Brazil to expand the study’s sample size and diversity.
- 2022: Laboratory experiments pinpoint the link between HOXD13 and the CD73/adenosine pathway.
- 2023: Mouse models demonstrate that inhibiting HOXD13 or its downstream targets (VEGF/adenosine) results in significant tumor regression.
- 2024: Publication in Cancer Discovery and the beginning of planning for targeted clinical trials.
The next steps for the NYU Langone team involve developing more direct ways to inhibit HOXD13 activity. While transcription factors are historically difficult to target with traditional drugs, new technologies such as proteolysis-targeting chimeras (PROTACs) or RNA-based therapies may offer a solution.
Institutional Support and Research Team
The success of this research was made possible through extensive institutional support and funding. The study received significant grants from the National Institutes of Health (NIH), including P30CA016087, R01CA274100, P50CA225450, and U54CA263001. Additional financial backing was provided by the Melanoma Research Foundation and the Melanoma Research Alliance, highlighting the importance of non-profit advocacy in cancer breakthroughs.
The international collaboration included experts from the National Autonomous University of Mexico (UNAM) and the Brazilian National Cancer Institute (INCA). This global team brought together diverse expertise in pathology, bioinformatics, and immunology.
Key contributors from NYU Langone included Amanda Flores Yanke, Fatemeh Vand Rajabpour, Catherine Do, Ines Delclaux, Tara Muijlwijk, Robert Stagnitta, Theodore Sakellaropoulos, Michelle Krogsgaard, Ata Moshiri, Iman Osman, Jane Skok, Amanda Lund, and Markus Schober. The project also benefited from the insights of principal investigators Carla Daniela Robles-Espinoza in Mexico and Patricia Possik in Brazil.
As the oncology community continues to seek ways to overcome immunotherapy resistance, the discovery of HOXD13’s dual role provides a compelling new target. By simultaneously cutting off a tumor’s food supply and dismantling its immune shield, researchers hope to turn the tide against some of the most aggressive and difficult-to-treat cancers.
